Cargando…
Towards Personalized Medicine in Psoriasis: Current Progress
Although innovative targeted therapies have positively revolutionized psoriasis treatment shifting treatment goals to complete or almost complete skin clearance, primary or secondary lack of efficacy is still possible. Hence, identifying robust biomarkers that reflect the various clinical psoriasis...
Autores principales: | Camela, Elisa, Potestio, Luca, Ruggiero, Angelo, Ocampo-Garza, Sonia Sofia, Fabbrocini, Gabriella, Megna, Matteo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444142/ https://www.ncbi.nlm.nih.gov/pubmed/36071793 http://dx.doi.org/10.2147/PTT.S328460 |
Ejemplares similares
-
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
por: Ruggiero, Angelo, et al.
Publicado: (2022) -
A case of erythrodermic psoriasis successfully treated with apremilast
por: Megna, Matteo, et al.
Publicado: (2021) -
Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study
por: Megna, Matteo, et al.
Publicado: (2022) -
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting
por: Megna, Matteo, et al.
Publicado: (2022) -
Treatment of pediatric psoriasis with TNF-antagonists: a real-life single-center case series()
por: Megna, Matteo, et al.
Publicado: (2022)